Venlafaxine and tardive blepharospasm: A case report

Yu, Liang; Yeh, Wei-Chiang; Chong, Mian‐Yoon; Lin, Pao‐Yen; Chang, Yung‐Yee

doi:10.1016/j.pnpbp.2007.03.015

Cited by 18 publications

(22 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although our patient was receiving risperidone, we believe that myoclonus was induced by venlafaxine, once there was a complete remission after discontinuation of the drug. Venlafaxine was associated with other movements disorders as blepharoespams 2 and myoclonus in the setting of serotonin syndrome, which is a potentially fatal complication of the combined use of agents that enhance serotonin activity 3 , but we couldn´t find any report of myoclonus and venlafaxine without serotonin syndrome.…”

Section: Discussionmentioning

confidence: 77%

“…It is well described in the current literature the association of myoclonus with anticonvulsivants, antidepressants, antipsychotic, cephalosporin and carbapenem antibiotics 2,4,5 . Although our patient was receiving risperidone, we believe that myoclonus was induced by venlafaxine, once there was a complete remission after discontinuation of the drug.…”

Section: Discussionmentioning

confidence: 97%

“…There are several reports of myoclonus and other movements disorders induced by selective inhibitors of serotonin [2][3][4][8][9][10] . In one of them, Lauterbach reported myoclonus induced by fluoxetine in a patient with Pick disease 8 and postulated that might be an underlying hypersensitivity of 5HT 1A receptors in Pick's disease.…”

Section: Discussionmentioning

confidence: 99%

“…Certain commonly prescribed drugs cause movements disorders as myoclonic jerks and polymyoclonus in the absence of other signs of toxicity 2 . Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used for the treatment of depression, post traumatic stress disorder, obsessive compulsive disorders, chronic pain and menopausal symptoms 3,4 .…”

mentioning

confidence: 99%

See 3 more Smart Citations

Venlafaxine induced-myoclonus in a patient with mixed dementia

Dutra

Pedroso

Félix

et al. 2008

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 77%

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Venlafaxine induced-myoclonus in a patient with mixed dementia

Dutra

Pedroso

Félix

et al. 2008

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

“…Tardive blepharospasm develops during or within 3 months of discontinuation of treatment with dopamine antagonists (in the absence of other diseases or familial causes). Symptoms of tardive blepharospasm fluctuate, as they disappear during rest or sleep, while fatigue, anxiety, work, and light exacerbate the disorder [23][24][25][26].…”

Section: Tardive Blepharospasmmentioning

confidence: 99%

Motor Symptoms of Schizophrenia: Is Tardive Dyskinesia a Symptom or Side Effect? A Modern Treatment

Lerner

Miodownik

2011

Curr Psychiatry Rep

View full text Add to dashboard Cite

Abnormal involuntary dyskinetic movements in schizophrenia patients have been documented for more than 140 years. Clinicians should distinguish between two kinds of disturbances-spontaneous dyskinetic movements and movements induced by psychotropic medications-which may look familiar clinically. As a modern term, tardive dyskinesia (TD) is a potentially permanent neurological hyperkinetic movement disorder that occurs after months or years of taking psychotropic drugs. Several distinct forms of TD exist, specifically tardive akathisia, tardive blepharospasm, tardive dystonia, tardive gait, tardive myoclonus, tardive tremor, and tardive tics, and they have different pathophysiologies and treatment. The pathogenesis of TD remains unclear, and the pathophysiology is complex and multifactorial. Moreover, there is solid evidence of a genetic predisposition to TD. This article summarizes recent relevant publications concerning TD and the most recent studies regarding treatment of this disorder with antioxidative agents.

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2008

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Venlafaxine and tardive blepharospasm: A case report

Cited by 18 publications

References 16 publications

Venlafaxine induced-myoclonus in a patient with mixed dementia

Venlafaxine induced-myoclonus in a patient with mixed dementia

Motor Symptoms of Schizophrenia: Is Tardive Dyskinesia a Symptom or Side Effect? A Modern Treatment

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About